LLPS-based classification and a novel prognostic signature reveal NRF1 as a therapeutic target in pancreatic cancer
Weishen Wang, Yi Zhao, Songyao Jiang, Yiwei Zhou, Qinxin Yang, Dan Li, Yu Jiang, Haoda Chen, Xiaomei Tang, Linjie Ren, Jia Liu, Jiabin Jin, Da Fu, Hong Yu · 2026
Read LLPS-based classification and a novel prognostic signature reveal NRF1 as a therapeutic target in pancreatic cancer by Weishen Wang, Yi Zhao, Songyao Jiang, Yiwei Zhou, Qinxin Yang, Dan Li, Yu Jiang, Haoda Chen, Xiaomei Tang, Linjie Ren, Jia Liu, Jiabin Jin, Da Fu, Hong Yu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13563917.txt.
Description
Weishen Wang and a large co-author group present a 2026 analysis of pancreatic ductal adenocarcinoma that groups tumors by regulators of liquid-liquid phase separation, a process that forms droplet-like structures inside cells. Using data from 176 patients, the group defined three tumor subtypes and built a risk score linked to those subtypes.
The subtypes differed in outlook, immune makeup, and predicted response to immune therapy, and the risk score held up across cohorts. Laboratory work singled out a protein called NRF1, which switched on several risk genes and helped tumor cells grow. Blocking it slowed tumors in experiments, making it a candidate target for further drug work.
Catalog record
| CREATOR | Weishen Wang, Yi Zhao, Songyao Jiang, Yiwei Zhou, Qinxin Yang, Dan Li, Yu Jiang, Haoda Chen, Xiaomei Tang, Linjie Ren, Jia Liu, Jiabin Jin, Da Fu, Hong Yu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 64680 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |